Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,008 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The golden hour of prehospital reperfusion with triple antiplatelet therapy: a sub-analysis from the Ongoing Tirofiban in Myocardial Evaluation 2 (On-TIME 2) trial early initiation of triple antiplatelet therapy.
Heestermans T, van 't Hof AW, ten Berg JM, van Werkum JW, Boersma E, Mosterd A, Stella PR, van Zoelen AB, Gosselink AT, Kochman W, Dill T, Koopmans PC, van Houwelingen G, Zijlstra F, Hamm C. Heestermans T, et al. Among authors: boersma e. Am Heart J. 2010 Dec;160(6):1079-84. doi: 10.1016/j.ahj.2010.08.039. Am Heart J. 2010. PMID: 21146661 Clinical Trial.
Reperfusion strategies in acute myocardial infarction.
Boersma E, Simoons ML. Boersma E, et al. Eur Heart J. 1997 Nov;18(11):1703-11. doi: 10.1093/oxfordjournals.eurheartj.a015163. Eur Heart J. 1997. PMID: 9402443 Review. No abstract available.
Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT.
Akkerhuis KM, Deckers JW, Boersma E, Harrington RA, Stepinska J, Mahaffey KW, Wilcox RG, Lincoff AM, Keltai M, Topol EJ, Califf RM, Simoons ML. Akkerhuis KM, et al. Among authors: boersma e. Eur Heart J. 2000 Mar;21(5):371-81. doi: 10.1053/euhj.1999.1743. Eur Heart J. 2000. PMID: 10666351 Clinical Trial.
Value of coronary stenotic flow velocity acceleration on the prediction of long-term improvement in functional status after angioplasty.
Albertal M, Regar E, Piek JJ, Van Langenhove G, Carlier SG, Thury A, Sianos G, Boersma E, de Bruyne B, di Mario C, Serruys PW; Doppler Endpoints Balloon Angioplasty Trial Europe (DEBATE) Study Group. Albertal M, et al. Among authors: boersma e. Am Heart J. 2001 Jul;142(1):81-6. doi: 10.1067/mhj.2001.115590. Am Heart J. 2001. PMID: 11431661
Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker.
Ronner E, Boersma E, Akkerhuis KM, Harrington RA, Lincoff AM, Deckers JW, Karsch K, Kleiman NS, Vahanian A, Topol EJ, Califf RM, Simoons ML. Ronner E, et al. Among authors: boersma e. Eur Heart J. 2002 Feb;23(3):239-46. doi: 10.1053/euhj.2001.2736. Eur Heart J. 2002. PMID: 11792139 Clinical Trial.
Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA.
Lenderink T, Boersma E, Heeschen C, Vahanian A, de Boer MJ, Umans V, van den Brand MJ, Hamm CW, Simoons ML; CAPTURE Investigators. Lenderink T, et al. Among authors: boersma e. Eur Heart J. 2003 Jan;24(1):77-85. doi: 10.1016/s0195-668x(02)00322-6. Eur Heart J. 2003. PMID: 12559939 Clinical Trial.
1,008 results